"YES Bank will raise the funds through a combination of about $640 million in shares and about $475 million in share warrants. It will offer 3.69 billion shares to affiliates of Carlyle Group and Advent. The company will also issue 2.56 billion share warrants at a price of Rs 14.82 per warrant to both the investors," the private lender said in a statement.
Consequent to the capital infusion, the bank’s CET-1 ratio (based on FY2022) would improve by ~380bps to 15.4 per cent and total capital adequacy ratio would improve to 21 per cent. The impact on book value per share is quite negligible given that the stock is trading closer to book value but the infusion would result in ~15 per cent dilution to EPS keeping all other variables unchanged.
"This, along with the recent announcement of transferring bad loans to an ARC can result in the bank putting back all its legacy issues. However, the bank still needs to build a strong liability franchise and invest in key resources to compete on like-to-like basis. This would take time as the bank lacks a strong profitable moat," said analysts at Kotak Institutional Equities.
It added that nearly all mid-tier banks are stepping up their growth engines and looking at faster normalization of long-term return ratios. YES Bank, it said, is also in a similar situation with the only exception with no strong profit pools readily available.
"There is a possibility of long periods of low credit costs if the recovery of bad loans from the sale of ARCs is better-than-anticipated. However, it is too early to forecast them. This lack of differentiation and a valuation that reflects the current situation prevents us from being constructive," it said with a "sell" rating and a fair value of Rs 13.
 "YES Bank")
